Market Cap 8.99B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 15.95
Forward PE 13.26
Profit Margin 43.74%
Debt to Equity Ratio 4.54
Volume 1,121,500
Avg Vol 1,800,988
Day's Range N/A - N/A
Shares Out 116.97M
Stochastic %K 89%
Beta 1.19
Analysts Sell
Price Target $70.56

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Bulldog344
Bulldog344 Sep. 12 at 2:57 PM
$HALO management rewards themselves with option shares-then sell out?
0 · Reply
Tcuduke
Tcuduke Sep. 12 at 12:37 AM
$HALO Doing something right when the shorties start crawling out.
0 · Reply
Antwan61186
Antwan61186 Sep. 11 at 7:24 PM
$HALO such a drop imminent
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 1:34 PM
$HALO Brilliant piece that captures HALO's situation perfectly. So if you want to update your understanding of HALO or get to know HALO better, this is essential reading. https://beyondspx.com/quote/HALO/analysis/halozyme-unlocking-blockbuster-potential-with-a-patented-delivery-engine-halo
0 · Reply
Halo202
Halo202 Sep. 8 at 9:20 PM
$HALO $78+ by Friday
0 · Reply
Okadarlan
Okadarlan Sep. 8 at 3:03 PM
$HALO should be the top .
1 · Reply
Sean29md
Sean29md Sep. 6 at 8:29 AM
$HALO Another clue/bread-crumb in Helen's talk at WF earlier this week: "Yes, we’re very active in discussions with a whole range of types of opportunities." "We definitely are getting this, and I’d say the areas of focus are oncology, inflammation and immunology, neurology, and nephrology." This is the first time (at least based on my memory) that she has mentioned "nephrology." I don't think there is currently anything the pipeline for nephrology. This could be a hint for new partnerships. https://www.investing.com/news/transcripts/halozyme-at-wells-fargo-conference-strategic-growth-and-challenges-93CH-4225631
0 · Reply
Sean29md
Sean29md Sep. 5 at 12:51 PM
$HALO From the transcript of yesterday's WF conference, Helen on halozyme vs. Merck: "We’re very confident we’re going to win it. We are able to know the structure of their modified hyaluronidase that’s being used because it’s published in the patents and it’s also available on the NIH website. That is what in part gives us such confidence in our ability to prevail because we know it is identical to sequences that we patented many, many years ago." "The PTAB agreed to institute four of them, which means that we will go forward to have those heard in a full PTAB review between March and June of next year. The outcome of that could be the patents are upheld or they’re invalidated.” “It doesn’t actually matter what the outcome there is because we have got patents that are in our district court case that are not subject to this PGR review because they were issued so long ago.”
0 · Reply
Sean29md
Sean29md Sep. 4 at 2:38 PM
$HALO The max strike price of the capped call options halozyme purchased in 2022 was $75.41 (see link below). Don't be surprised if Halozyme converted those options for a hefty sum of cash with which it can pay off the convertible bonds. In retrospect, that was a brilliant move. I remeber how Fred and easycomeandgo poopooed ut at the time (2022). https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-announces-upsize-and-pricing-of-private-offering-of-625-million-of-convertible-senior-notes-due-2028-301606130.html
0 · Reply
justanotheropinion
justanotheropinion Sep. 3 at 9:24 PM
$AVDL I'm only a dumb trader who scans a few recent quarterly earnings & analyzes price & volume action (they all look great), so I can't comment on the work done by Wells Fargo. An overweight rating would've helped the case, but I remain optimistic because of how the market reacted. Today's reaction tells me that while the market acknowledged the analysis, it didn't care that much. The price remains above its fast-moving average (10-day EMA), buyers stepped in and absorbed the selling pressure (green volume delta + largest volume since the earnings report). An example of a stock from the same sector, when the market cared much more after an analyst published his underwhelming rating, was $HALO on 13 May 2025—don't ask me why I remember it so vividly. Overall, $AVDL remains one of my biggest holdings
0 · Reply
Latest News on HALO
Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 16 days ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 17 days ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 2 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 4 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 4 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 6 months ago

Halozyme Joins the $1 Billion Club


Halozyme: Recent Approvals Alter My Appetite

Dec 31, 2024, 2:41 AM EST - 9 months ago

Halozyme: Recent Approvals Alter My Appetite


Halozyme to Present at Upcoming Investor Conferences

Nov 27, 2024, 8:30 AM EST - 10 months ago

Halozyme to Present at Upcoming Investor Conferences


Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 10 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO


Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 10 months ago

Halozyme CEO: Evotec Is Poised for Growth

EVO


Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 5, 2024, 12:24 PM EST - 11 months ago

Halozyme: Looking For More Growth Following Record Q3 Earnings


Halozyme Announces Record Earnings, Guidance

Nov 1, 2024, 11:42 AM EDT - 11 months ago

Halozyme Announces Record Earnings, Guidance


Bulldog344
Bulldog344 Sep. 12 at 2:57 PM
$HALO management rewards themselves with option shares-then sell out?
0 · Reply
Tcuduke
Tcuduke Sep. 12 at 12:37 AM
$HALO Doing something right when the shorties start crawling out.
0 · Reply
Antwan61186
Antwan61186 Sep. 11 at 7:24 PM
$HALO such a drop imminent
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 1:34 PM
$HALO Brilliant piece that captures HALO's situation perfectly. So if you want to update your understanding of HALO or get to know HALO better, this is essential reading. https://beyondspx.com/quote/HALO/analysis/halozyme-unlocking-blockbuster-potential-with-a-patented-delivery-engine-halo
0 · Reply
Halo202
Halo202 Sep. 8 at 9:20 PM
$HALO $78+ by Friday
0 · Reply
Okadarlan
Okadarlan Sep. 8 at 3:03 PM
$HALO should be the top .
1 · Reply
Sean29md
Sean29md Sep. 6 at 8:29 AM
$HALO Another clue/bread-crumb in Helen's talk at WF earlier this week: "Yes, we’re very active in discussions with a whole range of types of opportunities." "We definitely are getting this, and I’d say the areas of focus are oncology, inflammation and immunology, neurology, and nephrology." This is the first time (at least based on my memory) that she has mentioned "nephrology." I don't think there is currently anything the pipeline for nephrology. This could be a hint for new partnerships. https://www.investing.com/news/transcripts/halozyme-at-wells-fargo-conference-strategic-growth-and-challenges-93CH-4225631
0 · Reply
Sean29md
Sean29md Sep. 5 at 12:51 PM
$HALO From the transcript of yesterday's WF conference, Helen on halozyme vs. Merck: "We’re very confident we’re going to win it. We are able to know the structure of their modified hyaluronidase that’s being used because it’s published in the patents and it’s also available on the NIH website. That is what in part gives us such confidence in our ability to prevail because we know it is identical to sequences that we patented many, many years ago." "The PTAB agreed to institute four of them, which means that we will go forward to have those heard in a full PTAB review between March and June of next year. The outcome of that could be the patents are upheld or they’re invalidated.” “It doesn’t actually matter what the outcome there is because we have got patents that are in our district court case that are not subject to this PGR review because they were issued so long ago.”
0 · Reply
Sean29md
Sean29md Sep. 4 at 2:38 PM
$HALO The max strike price of the capped call options halozyme purchased in 2022 was $75.41 (see link below). Don't be surprised if Halozyme converted those options for a hefty sum of cash with which it can pay off the convertible bonds. In retrospect, that was a brilliant move. I remeber how Fred and easycomeandgo poopooed ut at the time (2022). https://www.prnewswire.com/news-releases/halozyme-therapeutics-inc-announces-upsize-and-pricing-of-private-offering-of-625-million-of-convertible-senior-notes-due-2028-301606130.html
0 · Reply
justanotheropinion
justanotheropinion Sep. 3 at 9:24 PM
$AVDL I'm only a dumb trader who scans a few recent quarterly earnings & analyzes price & volume action (they all look great), so I can't comment on the work done by Wells Fargo. An overweight rating would've helped the case, but I remain optimistic because of how the market reacted. Today's reaction tells me that while the market acknowledged the analysis, it didn't care that much. The price remains above its fast-moving average (10-day EMA), buyers stepped in and absorbed the selling pressure (green volume delta + largest volume since the earnings report). An example of a stock from the same sector, when the market cared much more after an analyst published his underwhelming rating, was $HALO on 13 May 2025—don't ask me why I remember it so vividly. Overall, $AVDL remains one of my biggest holdings
0 · Reply
SilverEagle
SilverEagle Aug. 29 at 1:43 AM
$HALO if sentiment changes in $XBI heading into year end with rates, etc. then this will continue to be a leader more than likely. The move past 100 will be quick.
0 · Reply
Tcuduke
Tcuduke Aug. 27 at 9:01 PM
$HALO Wish i had taken my own advice and bought more
1 · Reply
zebriod
zebriod Aug. 27 at 1:53 PM
$HALO on it's way to fair value
0 · Reply
Moominvalley
Moominvalley Aug. 27 at 1:47 AM
0 · Reply
Ferulic
Ferulic Aug. 26 at 7:16 PM
$HALO https://www.sandoz.com/sandoz-signs-non-binding-term-sheet-evotec-se-acquire-its-just-evotec-biologics-house-development/ Halozyme should seize this unique opportunity and buy EVOTEC! €6 is a great bargain! Just a few months ago, the price was €11. Those who are too late will not be able to buy growth at a low price, or will Novo Nordisk, Sandaoz, Genmab, or finally Halozyme come along? It was not so long ago that Halozyme made a takeover bid for Evotec AG shares at €11. Now, the share price is a whopping €5 BELOW the offer price at that time. The current market capitalization is only €950 million, which is an absolute bargain considering the global opportunities for biosimilars! The market for biosimilars alone is expected to be worth $300 billion over the next 10 years.
1 · Reply
Estimize
Estimize Aug. 25 at 1:00 PM
Wall St is expecting 1.59 EPS for $HALO Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/halo?chart=historical&metric_name=eps&utm_co
0 · Reply
TradeInYourJob
TradeInYourJob Aug. 25 at 12:44 AM
$HALO no position currently. Great run, but I think it's running out of juice
0 · Reply
Halo202
Halo202 Aug. 24 at 11:05 PM
$HALO $74+ this week
0 · Reply
cocokraken
cocokraken Aug. 24 at 2:49 PM
$HALO This is a great video. I think you’ll like it if you’re into Halo Therapeutics https://youtu.be/RaV-B-MHQ_k?si=8n0VBu3CNah0MVz3
0 · Reply
Sean29md
Sean29md Aug. 23 at 3:03 PM
$HALO The Reuters Report (see attached screenshots) will tell you all you need to know about halozyme's valuations compared to its peers and compared to its own past.
0 · Reply
Sean29md
Sean29md Aug. 23 at 2:42 PM
$HALO Proud of this post from May 2025: "Post: #10244 biotechinvestor1 05/05/2025, 2:59 PM Re: biotechinvestorl Last time Halo presented at BOA was in 2020. 2020 was a pivotal year for halo as it turned profitable and the stock had a massive run up (from $15 to high $40's). Don't be surprised if we have another pivotal year in 2025 with our first HVAl deal and a massive run up in share price. At a 2025 PE of 12, Halo is like a loaded spring ready to fire with any good news!" Congrats to the longs on this board! Bacause EPS has grown much faster than share price, we are still at a 2025 PE of 12. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios Still an amazing bargain. Market is recognizing this and will continue to re-rate halozyme to much higher levels.
0 · Reply
PapaFitz
PapaFitz Aug. 22 at 5:04 PM
$HALO this kind of sums up stocktwits
0 · Reply